Obesity care guidance refreshed
A recent review restated that obesity is a chronic disease and recommended treatments that go beyond simple diet and exercise. The American Journal of Managed Care summarized current guidance as a multi‑modal approach including structured lifestyle intervention, behavioral support, pharmacotherapy, and bariatric surgery where appropriate (ajmc.com).
Obesity care in the United States is increasingly treated as long-term disease management, not a short-term order to “eat less and move more.” (ajmc.com) A 2022 review in The American Journal of Managed Care said the field’s main adult guidelines still rest on the 2013 American College of Cardiology, American Heart Association, and The Obesity Society document and the 2016 American Association of Clinical Endocrinologists and American College of Endocrinology document, with later updates layered on top. That review said body mass index starts the evaluation, but clinicians should also check for weight-related conditions to judge disease severity and choose treatment. (ajmc.com) The review said lifestyle therapy remains the foundation of care, but medicines and metabolic or bariatric surgery produce greater and more durable weight loss than lifestyle changes alone in eligible patients. It also described obesity as a “serious, progressive, chronic disease” that needs an ongoing patient-clinician partnership. (ajmc.com) That approach lines up with current federal public health language. The Centers for Disease Control and Prevention says obesity is a “common, serious, and costly chronic disease,” and a February 2026 federal report estimated that 40.3% of United States adults had obesity in August 2021 through August 2023, including 9.7% with severe obesity. (cdc.gov; cdc.gov) Drug treatment has changed the conversation since those older guidelines were written. The Food and Drug Administration approved Wegovy, the semaglutide 2.4 milligram weekly injection, on June 4, 2021 for chronic weight management in adults with obesity or adults with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. (fda.gov) The same Food and Drug Administration notice said Wegovy is indicated for adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related ailment. It also listed common side effects including nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue, plus a boxed warning about thyroid C-cell tumors. (fda.gov) Surgery guidance has shifted too. In 2022, the American Society for Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders said metabolic and bariatric surgery is recommended for people with a body mass index above 35 regardless of coexisting conditions, and should be considered for people with metabolic disease and a body mass index of 30 to 34.9. (asmbs.org) Newer specialty guidance has moved further toward individualized care. The American Association of Clinical Endocrinology’s 2025 consensus statement said treatment intensity should be tailored to disease severity, that care should be person-centered and complication-focused, and that reducing weight bias and stigma is part of treatment. (endocrinepractice.org) The practical message for clinicians is not that diet and exercise disappeared. It is that current guidance places structured nutrition and activity plans, behavioral support, anti-obesity medicines, and surgery on the same treatment map, with different options used for different patients over time. (ajmc.com; endocrinepractice.org)
